



## Preliminary programme

### Moderators:

Morgan Roupret, Paris (FR)  
Arnulf Stenzl, Tübingen (DE)

### 13.00 – 14.00 Update on staging of PCa

#### 13.00 – 13.10 Magnetic Resonance Imaging (bp or mpMRI) for diagnosis and staging

Jochen Walz, Marseille (FR)

#### 13.10 - 13.15 *Discussant*

TBC

#### 13.15 – 13.25 PSMA based imaging in primary and recurrent disease

TBC

#### 13.25 – 13.30 *Discussant*

Jochen Walz, Marseille (FR)

#### 13.30 – 13.35 Breaking news from the Guidelines 2020 on staging

Nicolas Mottet, Saint-Étienne (FR)

#### 13.35 – 14.00 What is the best and most effective staging in 2020? (interactive case discussions)

TBC

Jochen Walz, Marseille (FR)

TBC

### 14.10 – 15.10 Update on the treatment of recurrent disease

#### 14.10 – 14.20 BCR after surgery: early or late salvage RT

Gert De Meerleer, Leuven (BE)

#### 14.20 – 14.25 *Discussant*

Alberto Briganti, Milan (IT)

#### 14.25 – 14.35 Management of oligometastatic recurrence

Alberto Briganti, Milan (IT)

#### 14.35 – 14.40 *Discussant*

Gert de Meerleer, Leuven (BE)

#### 14.40 – 14.45 Breaking news from the Guidelines 2020 on recurrent disease

Nicolas Mottet, Saint-Étienne (FR)

#### 14.45 – 15.10 The best timing of different forms of treatment in recurrent disease (Interactive Case Discussion)

Alberto Briganti, Milan (IT)

Gert De Meerleer, Leuven (BE)

Jeroen Van Moorselaar, Amsterdam (NL)

**15.20 – 16.20 Update on the treatment of de novo low-volume mHSPC**

**15.20 – 15.30 How to manage node positive (cN1/cM1a) PCa**

Steven Joniau, Leuven (BE)

**15.30 – 15.35 *Discussant***

TBC

**15.35 – 15.45 Management options of low-volume mHSPC**

TBC

**15.45 – 15.50 *Discussant***

Steven Joniau, Leuven (BE)

**15.50 – 15.55 Breaking news from the Guidelines 2020 on staging and treatment of HSPC**

Nicolas Mottet, Saint-Étienne (FR)

**15.55 – 16.20 How much local treatment for low volume mHSPC? ( Interactive Case Discussion)**

TBC

Nicola Fossati, Milan (IT)

Steven Joniau, Leuven (BE)

**16.30 – 17.30 Update on the treatment of CRPC**

**16.30 – 16.40 Update on the management of non-metastatic CRPC**

Axel Merseburger, Lübeck (DE)

**16.40 – 16.45 *Discussant***

Joaquim Bellmunt, Barcelona (ES)

**16.45 – 16.55 New developments in the management of mCRPC**

Joaquim Bellmunt, Barcelona (ES)

**16.55 – 17.00 *Discussant***

Derya Tilki, Hamburg (DE)

**17.00 – 17.05 Breaking news from the Guidelines 2020 on CRPC**

Nicolas Mottet, Saint-Étienne (FR)

**17.05 – 17.30 Best sequence of CRPC (Interactive Case Discussion)**

Joaquim Bellmunt, Barcelona (ES)

Axel Merseburger, Lübeck (DE)

Derya Tilki, Hamburg (DE)